跳至主要内容
临床试验/IRCT20200408046990N7
IRCT20200408046990N7招募中2 期

Evaluation of oral nano-formulation of Curcumin efficacy, as an adjuvant to Capecitabine [Xeloda] + Oxaliplatin (XELOX) or Folinic Acid + 5-Flurouracil + Oxaliplatin (FOLFOX) regimen treatment for metastatic colorectal cancer: A triple blinded, randomized clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • Patients with confirmed histological or cytological diagnosis of metastatic colorectal cancer (stage 4) Based on ultrasound results without NRAS and KRAS mutation or no candidate for target therapy(Contraindications or economic incapability)
  • XELOX or FOLFOX regimen candidate
  • Patient consent to study
  • Eastern cooperative oncology group (ECOG) 0/ 1
  • Hemoglobin=9g/dL? Neutrophil count=1.5×103/µL, Platelet count=10×104/µLCreatinine=1.5 mg/dl, ALT,AST =5 ×ULN? total bilirubin=2×

排除标准

  • current antioxidant users
  • pregnancy or lactation
  • history of hypersensitivity to formulation components
  • diagnosed with more than one cancer
  • history of HF
  • history of autoimmune or immunodeficiency (medical or drug induced) other than chemotherapy
  • history of HBV or HCV
  • candidate of curative surgery

研究者

相似试验